🟢 Outlook Therapeutics is trading 5.33% up today after $485-per-vial LYTENAVA pricing announcement

Outlook Therapeutics is trading at $0.69, up 5.33%, as attention extends around the September 18 announcement of a $485-per-vial U.S. wholesale price for LYTENAVA.

• The pricing establishes an important commercial milestone ahead of the planned U.S. launch and may improve visibility into potential product economics.
• Broader risk appetite also supports trading, with the S&P 500 up 1.00% and NASDAQ Composite up 1.50%.